General Information of Drug (ID: DMJOD1T)

Drug Name
3-Phenylcyclopentanecarboxylic acid Drug Info
Synonyms
3-Phenylcyclopentanecarboxylic acid; 91495-75-9; 3-phenylcyclopentane-1-carboxylic acid; CHEMBL554283; 3-phenyl-cyclopentanecarboxylic acid; SCHEMBL1073107; CTK3I5725; DTXSID80605012; MolPort-020-002-441; BDBM50293437; CP-858; Cyclopentanecarboxylicacid, 3-phenyl-; 3-phenyl-1-cyclopentanecarboxylic acid; AKOS022536861; A843950
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
20313173
CAS Number
CAS 91495-75-9
TTD Drug ID
DMJOD1T

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [2]
ASP-9521 DM8V0UL Prostate cancer 2C82.0 Phase 1/2 [3]
N-(benzimidazole/indole) benzoic acid derivative 2 DMOPUFM N. A. N. A. Patented [4]
N-(phenylamino)-benzoate derivative 1 DMNIWVG N. A. N. A. Patented [4]
Indomethacin analog 3 DM53JXE N. A. N. A. Patented [4]
Indomethacin analog 2 DMKFPJ7 N. A. N. A. Patented [4]
Beta-naphthylacetic acids derivative 1 DM5KTDY N. A. N. A. Patented [4]
Indomethacin analog 1 DM3E5V6 N. A. N. A. Patented [4]
N-(naphthylamino)-benzoate derivative 1 DM310ES N. A. N. A. Patented [4]
N-(benzimidazolylcarbonyl)-piperidine derivative 1 DM541QW N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dihydrodiol dehydrogenase type I (AKR1C3) TT5ZWB6 AK1C3_HUMAN Inhibitor [1]

References

1 New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71.
2 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
3 Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004.
4 Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.